Hepion Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $1.65M
- P/E (TTM)
- –
- Dividend yield
- –
About Hepion Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Hepion Pharmaceuticals, Inc. operates as a medical diagnostic company focused on diagnostic solutions. The company previously concentrated on developing drug therapies for chronic liver conditions, specifically its cyclophilin inhibitor rencofilstat, before divesting all related patent assets, clinical data, and drug materials. Currently, Hepion in-licenses diagnostic tests covering conditions such as celiac disease, respiratory multiplex infections, Helicobacter pylori, and hepatocellular carcinoma, alongside licensed liver disease diagnostic assets. It targets healthcare markets seeking clinical diagnostic tools.
The company maintains its principal executive offices in Morristown, New Jersey. Its licensed tests for celiac disease, respiratory multiplex, and Helicobacter pylori hold CE marks, making them eligible for commercial sale within the European Union and other participating territories that recognize CE certification, while excluding the United States. Hepion does not possess internal commercialization, sales, marketing, or manufacturing facilities, relying instead on external arrangements and collaborations to advance and distribute its diagnostic product portfolio across authorized regional markets.
Summary of the business section of Hepion Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Hepion Pharmaceuticals, Inc.
- Headquarters
- Red Bank, NJ
- Address
- 34 Shrewsbury Ave., Suite 1d 07701
- Phone
- (732) 902-4000
- Employees
- 2, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Grassi & Co., CPAs, P.C, Jericho, New York
Stock & identifiers
- Ticker
- HEPA
- Other tickers
- CTRVP
- Exchange
- OTC
- Shares outstanding
- 90M, Aug 10, 2026
- Public float
- $900.00K, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-50 reverse, Apr 8, 2025; 1-for-50 reverse, Mar 18, 2025; 1-for-20 reverse, May 11, 2023; 1-for-20 reverse, May 3, 2023; 1-for-70 reverse, Jun 3, 2019; 1-for-70 reverse, May 28, 2019; 1-for-8 reverse, May 29, 2018; 1-for-8 reverse, May 25, 2018
- SEC CIK
- 1583771
- EIN
- 46-2783806
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Vincent S. LoPriore | Executive Chairman, Director | 30,500,000 |
| Gary S. Stetz | Interim CEO, Director | 4,500,000 |
| Chase LoPriore | VP, Corp. Dev., Director | 1,250,000 |
| Sireesh Appajosyula | Chief Operating Officer, Director | 3,250,000 |
| Michael J. Purcell | Director | 3,250,000 |
| James Gordon Liddy | Director | – |
| Danina Fisher | Director | – |
| Gary S. Stetz II | Director | 500,000 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had two employees.”
Corporate history
Events identified from SEC filings